Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2029-02-21
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of isatuximab, carfilzomib, and pomalidomide in
treating patients with multiple myeloma that has come back (relapsed) or does not respond to
treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the
ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as
pomalidomide, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
isatuximab, carfilzomib, and pomalidomide may help treat patients with multiple myeloma.